VHH Antibody

VHH antibodies are single-domain antibody fragments derived from the unique heavy-chain-only antibodies (HCAbs) of camelids, including alpacas, llamas, and camels.

Antibody thermal stability refers to the ability of an antibody to retain its structural conformation and binding function when exposed to elevated temperatures. It includes both chemical and physical aspects of protein integrity. Thermal stability is especially critical in therapeutic and diagnostic applications where antibodies must remain effective during manufacturing, shipping, storage, and use.

Discover how immune, naïve and synthetic VHH libraries are built, biopanned and optimized for therapeutic, diagnostic, imaging and research use globally now.

Learn how synthetic phage-displayed VHH libraries are designed and built. Explore workflows, advantages, applications, and challenges in antibody discovery.

Antibody fragments have become indispensable in modern biotechnology due to their smaller size, improved tissue penetration, and suitability for engineered constructs. Among these, camelid VHH nanobodies (single-domain antibodies) and single-chain variable fragments (scFvs) represent two widely studied and applied formats. Both can be produced recombinantly and tailored for diagnostic or therapeutic use, yet their origins, molecular structures, and functional properties are distinct.

VHH antibodies, also called single-domain antibodies or nanobodies, are the smallest functional fragments of antibodies capable of binding antigens. They originate from the heavy-chain-only antibodies found in camelids such as llamas and camels. Unlike conventional antibodies, which require both heavy and light chains for antigen recognition, VHHs operate as a single domain.

Camelid antibodies are specialized immunoglobulins naturally found in llamas, alpacas, and camels. Unlike conventional antibodies that use both heavy and light chains, camelids produce a unique form known as heavy-chain-only antibodies. Their variable domain, called the VHH or single-domain antibody, retains full antigen-binding activity even without light chains.

VHH libraries provide diverse nanobody options. Biointron builds and screens libraries to identify stable, high-affinity binders for diagnostics and therapeutics.

Camelids provide the origin of VHH antibodies. Biointron highlights their unique biology, how VHHs are developed, and their growing use in diagnostics and therapy.

VHH antibodies offer stability, small size, and strong binding. Biointron highlights their promise in diagnostics, therapeutics, and next-generation antibody design.

VHH antibodies have reshaped biotech. Biointron reviews their discovery, unique advantages, and applications driving innovation in diagnostics and therapeutic development.

The alpaca advantage: VHH discovery powered by unique immune repertoires. See how Biointron leverages alpaca libraries for robust nanobody identification.